Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease - A prospective study

Thrombosis Research

Volumn 103, Issue 2, 2001, Pages 93-101

  Nowak Gottl U ^a,b   Kotthoff, S ^a   Hagemeyer, E ^a   Junker, R ^b   Kehl, Hg ^a   Vielhaber, H ^c   Kececioglu, D ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cardiac disease; Factor V G1691A; Lipoprotein (a); PAI 1; t PA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ARTICLE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; CHILD; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART CATHETERIZATION; HEART SURGERY; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; THROMBOEMBOLISM;

3' UNTRANSLATED REGIONS; ADOLESCENT; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHILD; CHILD, PRESCHOOL; FACTOR V; FIBRINOLYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; LIPOPROTEIN(A); PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PREVALENCE; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; PROTEIN C DEFICIENCY; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035878754     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00281-X     Document Type: Article

References (34)

1. Developmental haemostasis: Relevance to thromboembolic complications in paediatric patients
2. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
3. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
4. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
5. Thromboembolism and resistance to activated protein C in children with underlying cardiac disease
6. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood
7. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia
8. Thrombosis in otherwise well children with the factor V Leiden mutation
9. Impact of weight loss on plasminogen activator inhibitor (PAI 1), factor VII, and other hemostatic factors in moderately overweight adults
10. Studies on the fibrinolytic system in human plasma: Quantitative determination of plasminogen activators and proactivators
11. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor 1 in patients with a history of ischemic stroke
12. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
13. Prospective study of endogenous tissue type plasminogen activator and risk of stroke
14. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden
15. The two allele sequences of a common polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
16. Catheter replacement of the needle in percutaneous arteriography: A new technique
17. Iliac vein-inferior caval thrombosis after cardiac catheterization in infancy
18. Vascular access in previously catheterised children and adolescents: A prospective study of 131 consecutive cases
19. Enhanced soluble thrombomodulin, t-PA and u-PA concentrations caused by short-term endothelial damage during percutaneous cardiac catheterisation
20. Plasma thrombomodulin concentrations in infants and children undergoing cardiac catheterization
21. Arg 506 to Gln mutation in the factor V gene causes poor fibrinolytic response in children after venous occlusion
22. Arginine 506 to glutamine mutation in the factor V gene in infancy and childhood: Evidence of fibrinolytic impairment
23. Allele specific PCR for detection of a sequence polymorphism in the promotor region of the plasminogen activator inhibitor-1 (PAI-1) gene
24. Mutation in blood coagulation factor V associated with resistance to activated protein C
25. Development of the hemostatic system in the neonate and young infant
26. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood
27. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 in children and adults
28. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns
29. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
30. FV R506Q mutation and elevated lipoprotein (a): A possible link to the plasminogen activator inhibitor-1 (PAI-21) 4G/5G genotype?
31. Mechanisms of fibrinolysis and clinical use of thrombolytic agents
32. Fibrinolysis in normal subjects: Comparison between plasminogen activator inhibitor and other components of the fibrinolytic system
33. Analysis of factors affecting tissue-type plasminogen activator activity and antigen concentrations before and after venous occlusion in 123 patients
34. Purification and characterisation of TAFI, a thrombin-activable fibrinolysis inhibitor